Title
p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Ruiz-Patiño A.
Rodríguez J.
Cardona A.F.
Ávila J.
Archila P.
Carranza H.
Vargas C.
Otero J.
Arrieta O.
Zatarain-Barrón L.
Sotelo C.
Ordoñez C.
García-Robledo J.E.
Rojas L.
Bermúdez M.
Gámez T.
Mayorga D.
Corrales L.
Martín C.
Recondo G.
Samtani S.
Ricaurte L.
Malapelle U.
Russo A.
Barrón F.
Santoyo N.
Rolfo C.
Rosell R.
Publisher(s)
Neoplasia Press, Inc.
Abstract
Background: The KRAS exon 2 p. G12C mutation in patients with lung adenocarcinoma has been increasing in relevance due to the development and effectiveness of new treatment medications. Studies around different populations indicate that regional variability between ethnic groups and ancestries could play an essential role in developing this molecular alteration within lung cancer. Methods: In a prospective and retrospective cohort study on samples from lung adenocarcinoma from 1000 patients from different administrative regions in Colombia were tested for the KRAS p.G12C mutation. An analysis of STR populations markers was conducted to identify substructure contributions to mutation prevalence. Results: Included were 979 patients with a national mean frequency for the KRAS exon 2 p.G12C mutation of 7.97% (95%CI 6.27–9.66%). Variation between regions was also identified with Antioquia reaching a positivity value of 12.7% (95%CI 9.1–16.3%) in contrast to other regions such as Bogota DC (Capital region) with 5.4% (2.7–8.2%) and Bolivar with 2.4% (95%CI 0–7.2%) (p-value = 0.00262). Furthermore, Short tandem repeat population substructures were found for eight markers that strongly yielded association with KRAS exon 2 p.G12C frequency reaching an adjusted R2 of 0.945 and a p-value of < 0.0001. Conclusions: Widespread identification of KRAS exon 2 p.G12C mutations, especially in cases where NGS is not easily achieved is feasible at a population based level that can characterize regional and national patterns of mutation status. Furthermore, this type of mutation prevalence follows a population substructure pattern that can be easily determined by population and ancestral markers such as STR.
Volume
15
Issue
1
Language
English
OCDE Knowledge area
Oncología Tecnología para la identificación y funcionamiento del ADN, proteínas y enzimas y como influencian la enfermedad) Radiología, Medicina nuclear, Imágenes médicas
Scopus EID
2-s2.0-85119498132
Source
Translational Oncology
Resource of which it is part
Translational Oncology
ISSN of the container
19365233
Sponsor(s)
Christian Rolfo reports relation with Mylan, Archer Biosciences, Oncopass, Inivata, Merck Serono Novartis, MSD, Boehringer Ingelheim, Guardant Health, etc. AstraZeneca as part of Speakers' Bureau. Also, he received research funding from Pfizer and had uncompensated Relationships with OncoDNA, Biomark, and Guardant Health. This work was financed in cooperation with Amgen Biotecnol?gica S.A.S. For administrative region reference, please refer to the following link: https://upload.wikimedia.org/wikipedia/commons/6/67/Departments_of_colombia.svg, Andr?s F. Cardona discloses financial research support from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Foundation Medicine, Roche Diagnostics, Termo Fisher, Broad Institute, Amgen, Flatiron Health, Teva Pharma, Rochem Biocare, Bayer, INQBox and The Foundation for Clinical and Applied Cancer Research ? FICMAC. Additionally, he was linked and received honoraria as an advisor, participate in speakers' bureau. He gave expert testimony to EISAI, Merck Serono, Jannsen Pharmaceutical, Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly, Guardant Health, Illumina, and Foundation for Clinical and Applied Cancer Research ? FICMAC. Oscar Arrieta reports personal fees from Pfizer, grants and individual fees from Astra Zeneca, grants and individual fees from Boehringer-Ingelheim, Lilly, Merck, Bristol Myers Squibb, Roche, outside the submitted work. Christian Rolfo reports relation with Mylan, Archer Biosciences, Oncopass, Inivata, Merck Serono Novartis, MSD, Boehringer Ingelheim, Guardant Health, etc. AstraZeneca as part of Speakers' Bureau. Also, he received research funding from Pfizer and had uncompensated Relationships with OncoDNA, Biomark, and Guardant Health. Gonzalo Recondo discloses travel, accommodations, and expenses from AstraZeneca and Pfizer, and consulting advisory role with Roche, Amgen, and Pfizer. Umberto Malapelle reports personal fees from Boehringer Ingelheim, AstraZeneca, Roche, MSD, Amgen, Merck, BMS for participation in a speaker bureau; personal fees from Boehringer Ingelheim, MSD, Amgen, Merck, BMS for acting in an advisory role, financial support from Boehringer Ingelheim and Amgen that was paid directly to his institution outside the submitted work.
Sources of information: Directorio de Producción Científica Scopus